Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TANGO: Switch to Dolutegravir/Lamivudine in Virologically Suppressed HIV-1 Adults
NCT03446573Phase 3Completed
- Sponsor
- ViiV Healthcare
- Start
- Jan 2018
- Primary completion
- May 2019
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 10
01
Overview
Phase 3, randomised, open-label trial of dolutegravir + lamivudine in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by ViiV Healthcare. Primary endpoint: Percentage of Participants With Virologic Failure Endpoint as Per FDA Snapshot Category at Week 48. Started Jan 2018; status: completed.
02
Drugs
dolutegravir + lamivudine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03446573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03446573.